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Abstract To avoid potentially severe outcomes, phenylke-
tonuria (PKU) must be detected as soon as possible after birth
and managed with life-long treatment. A questionnaire-based
survey was performed to document diagnosis and manage-
ment practices for PKU in a region of Southern and Eastern
Europe. Prevalence and management data were obtained from
37/59 (63 %) centres within 19/22 (86 %) contacted countries
(N=8600 patients). The main results’ analysis was based on
completed questionnaires obtained from 31 centres (53 %)
within 15 countries (68 %). A median of 10 % of patients
per centre had been diagnosed after the newborn period. Met-
abolic dieticians and specialised adult PKU clinics were
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lacking in 36 and 84 % of centres, respectively. In 26 % of
centres, treatment initiation was delayed until >15 days of life.
Blood phenylalanine (Phe) thresholds to start treatment and
upper Phe targets were inconsistent across centres. Ten per-
cent of centres reported monitoring Phe every 2 weeks for
pregnant women with PKU, which is insufficient to minimise
risk of neonatal sequalae. Sapropterin dihydrochloride treat-
ment was available in 48 % of centres, with 24-h responsive-
ness tests most common (36 %). Only one centre among the
five countries lacking newborn screening provided a complet-
ed questionnaire.
Conclusion: Targeted efforts by health care professionals
and governments are needed to optimise diagnostic and man-
agement approaches for PKU in Southern and Eastern Europe.
BWhat is Known^
• PKU must be detected early and optimally managed throughout life to
avoid poor outcomes, yet newborn screening is not universal and
diagnostic and management practices for PKU are known to vary
widely between different centres and countries.
• Targeted efforts by health care professionals and governments are
needed to optimise diagnostic and management approaches.
BWhat is New^
• PKU management practices are documented in 19 South and Eastern
European countries indicating a heterogeneous situation across the
region.
•Key areas for improvement identified in surveyed centres include a need
for comprehensive screening in all countries, increased number of
metabolic dietitians and specialised adult PKU clinics, delayed time to
treatment initiation, appropriate Phe thresholds, Phe targets and
monitoring frequencies, and universal access to currently available
treatment options.
Keywords Diagnosis .Management . Phenylketonuria .
Questionnaire . Sapropterin dihydrochloride . Screening .
Survey . Tetrahydrobiopterin
Abbreviations
BH4 Tetrahydrobiopterin or sapropterin dihydrochloride
DHPR Dihydropteridine reductase
HCP Health care professional
N/A Not applicable
Phe Phenylalanine
PKU Phenylketonuria
Introduction
Phenylketonuria (PKU; OMIM: #261600) is an inborn error
of phenylalanine (Phe) metabolism with an estimated average
prevalence in Europe of 1/10,000 live births [16]. Timely
newborn screening and life-long Phe-restricted diet enable
the severe outcomes of untreated PKU to be avoided [2].
Despite the cost-effective nature of newborn screening, it
has been reported that several countries either do not offer this
service or can offer it to only part of their population [3–5, 9,
10, 15, 20, 22–24, 30]. Furthermore, diagnostic and manage-
ment practices for PKU vary between countries. The present
study was conducted to describe the management and treat-
ment practices for PKU in an area comprising much of South
and Eastern Europe. The majority of these centres were not
captured by a previous European survey [1]. Based on socio-
economic factors such as gross domestic product per capita,
some of these countries might be expected to employ less
comprehensive management approaches for PKU than are in
use in more affluent regions of Western Europe. This survey
was designed to highlight the shortcomings in PKU manage-
ment and to facilitate the targeting of future initiatives.
Methods
Questionnaire development
A questionnaire consisting of 52 closed (answer choices pro-
vided) and 29 open answer questions was developed covering
the following topics: (1) general information; (2) screening
procedures and confirmatory diagnosis procedures; (3) treat-
ment practices; (4) follow-up; (5) constitution of treatment
team; (6) existing guidelines and protocols; (7) services of-
fered to patients; and (8) challenges and areas for improve-
ment in PKU management. The full survey is available in
Online Resource 1.
Invited health care professionals
An invitation with a link to the online questionnaire (Survey
Monkey: www.surveymonkey.com) was emailed to 80 health
care professionals (HCP) working in the field of PKU from 59
centres in 22 countries in South and Eastern Europe (see Fig. 1
and Appendix). Belarus was not included in this study be-
cause no HCP contacts were known. The Russian Federation
was not included due to difficulties in accessing health profes-
sionals, although many PKU treatment centres exist. The
questionnaire was only provided in English.
Data were collected from February to August 2014. A
maximum of three HCPs per centre were invited to participate.
To avoid inconsistencies in responses, all contributing HCPs
from the same centre were requested to complete a single
questionnaire.
Data analysis
Returned questionnaires were analysed for completeness:
questionnaires with incomplete answers beyond the ‘general
information’ section were excluded from the main results
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analysis, and the demographic data provided by these ques-
tionnaires were evaluated separately (see Sect. “Centres pro-
viding demographic data only/e-mail responses”). Informa-
tion provided by centres exclusively in e-mail form was also
evaluated separately (see Sect. “Centres providing demo-
graphic data only/e-mail responses”).
Data were analysed using descriptive statistics (percent of
total responses or medians). Prior to analysis, responses to
some open answer questions were grouped or categorised ac-
cording to the answers received. Answers were not systemat-
ically quality checked with the participating centres. Ques-
tions and answers not included in this report are summarised
in Online Resource 2.
Results
Contributing centres and HCPs
In total, information on the prevalence and management of
PKU was obtained from 37/59 (63 %) centres in 19/22
(86 %) contacted countries (Fig. 1). Complete questionnaires
were returned from 31 centres involving 60 HCPs in 15 coun-
tries. Incomplete questionnaires, which included only demo-
graphic data, and/or e-mail-only responses were returned from
six centres involving an additional four countries (Fig. 1; see
Sect. “Centres providing demographic data only/e-mail re-
sponses” for more details). Contributing HCPs and centres
are listed in Appendix.
Among the 60 HCPs returning complete questionnaires,
most were either metabolic paediatricians (43.3 %) or paedia-
tricians (30.0 %). Other professions included ‘clinical geneti-
cist’ (6.7 %); ‘dietician/nutritionist’ (6.7 %); ‘research scien-
tist’ (3.3 %); and ‘dietician, metabolic diseases’, ‘laboratory
technician’, ‘physician’, ‘adult metabolic doctor’, ‘nurse
specialising in PKU’ and ‘clinical biochemist’ (each 1.7 %).
These HCPs had a median (range) of 17 (1–41) years of PKU
clinical experience, and 75 % cared for patients of all ages
with PKU or maternal PKU.
Ten percent of centres reported that their PKU diagnosis
and treatment team consisted of physicians, clinical biochem-
ists, psychologists, dieticians and specialist nurses who care
for the PKU population, and 16.1 % of centres reported hav-
ing a specialised adult PKU clinic (Table 1). A dedicated di-
etician was part of the team in 65 % of centres, 70 % of whom
have a university degree.
Patients
In total, the 31 centres who returned complete questionnaires
followed a total of 8573 patients with PKU, of whom approx-
imately 75 % were followed in two countries, Turkey and
V
Country Centres Patients
Responded 
(contacted)
Median
per centre
Poland (PL) 8 (13) 189
Turkey (TR) 7 (11) 206
Romania (RO) 3,1a (4) 41,6c
Czech Republic (CZ) 2 (3) 343
Serbia (RS) 1,1a (2) 40,14c
Hungary (HU) 1 (2) 400
Croatia (HR) 1 (1) 140
Slovenia (SI) 1 (1) 130
Lithuania (LT) 1 (1) 100
Bulgaria (BG) 1 (1) 74
Latvia (LV) 1 (1) 73
Slovakia (SK) 1 (3) 70
Estonia (EE) 1 (1) 52
Moldova (MD) 1 (1) 42
Malta (MT) 1 (1) 3
Macedonia (MK) 1a (2) 5c
Bosnia and 
Herzegovina (BA) 1
a (1) 2c
Albania (AL) 1b (1) -
Montenegro (ME) 1b (1) -
Cyprus (CY) 0 (3) -
Kosovo (XK) 0 (1) -
Ukraine (UA) 0 (2) -
All 37 (59)
Sum
2373
4298
93,6c
685
40,14c
400
140
130
100
74
73
70
52
42
3
5c
2c
-
-
-
-
-
8600 100
All (complete surveys) 31 (59) 8573 102
Complete survey (15)
Incomplete survey and/or email response only (4)  
No data (3)
No newborn screening for PKU (5)
EE
LV
LT
PL
CZ
SK
HU
RO
MD
UA
BG
TR
MT
SI
HR
ME
XK
BA RS
CY
AL
MK
Fig. 1 Countries and centres participating in the survey. Information was
returned from 19/22 contacted countries, ordered in the list by the total
number of responding centres per country (high to low). ‘–’ data not
provided. aCentre provided only an incomplete questionnaire response;
bCentre provided only an email response with limited information;
cNumber of patients in centre providing the incomplete questionnaire,
not included in main results’ analysis
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Poland (Fig. 1). Data on patients and the HCPs working in the
treatment team at each centre are presented in Table 1. The
median number of patients per centre was 102 (range 3–2500),
with the largest centres in Turkey and Poland (Fig. 1). The
median number of new patients followed per year per centre
was 6 (range 1–50). Amedian of 10% (range 0–100) of patients
were late diagnosed, and only two centres had no late diagnosed
patients. Across the region, patients were estimated to travel a
median of 110 km (range 10–500 km) to their centre.
Screening and confirmatory diagnosis procedures
Among the completed questionnaires, only one centre in Mal-
ta had no newborn screening programme (Fig. 1, further in-
formation on screening practices presented in Table 2; see
Sect. “Centres providing demographic data only/e-mail re-
sponses” for responses from other countries lacking newborn
screening). Seventy-one percent of centres screened at 3 days
of age (median 3 days; range 2–7 days), and 77 % saw posi-
tively screened newborns within the first 15 days of life (me-
dian 10 days; range 3–30 days). The most common upper
threshold for a positive newborn screening test was a blood
Phe concentration of 120 μmol/L (48.4 %), followed by
180 μmol/L (25.8 %).
After a positive newborn screening test, diagnosis was con-
firmed by tandem mass spectrometry (39 %), amino acids chro-
matography (26 %), and/or a fluorescent, enzymatic or colori-
metric method (58 %). No centres reported relying on the Guth-
rie test for confirmatory diagnosis. Routine genetic analysis was
performed at 64.5 % of centres as part of their diagnostic proce-
dure (centres in Croatia (1/1), Romania (3/3), Turkey (5/7) and
Poland (1/7) did not conduct genetic analysis). Of the centres,
51.6 % performed routine sapropterin dihydrochloride
(tetrahydrobiopterin (BH4)) loading tests (newborns, 38.7 %;
older children, 32.3 %; adults, 3.2 %). This test is used to inves-
tigate a diagnosis of BH4-responsive PKU and/or to rule out
BH4 deficiency in newborns. At these centres, the BH4 loading
test dose was 20 mg/kg, BH4 responsiveness in PKU was con-
sistently defined as a reduction in Phe concentration of ≥30 %,
and the most common duration of the test was 24 h (35.5 %;
range 24 h–30 days). Amedian of 15% (range 0–31) of patients
were classified as BH4 responders. Other tests used to distin-
guish BH4 deficiency from PKU included pterins and
dihydropteridine reductase (DHPR) analysis (45.2 %).
Treatment practices and reimbursement
All centres advocated life-long treatment with a low-Phe diet
(based on Phe-free amino acid supplements and special low-
Table 1 Summary of patients with PKU and management team profile (N=31)
Question and answers by category Median
(range)
How many PKU patients are currently followed at your clinic/centre? 102 (3–2500)
1–25 26–50 51–100 101–200 201–500 ≥501
12.9 % 9.7 % 22.6 % 16.1 % 22.6 % 12.9 %
What is the number of new PKU patients followed over the course of a typical year at your clinic/centre? 6 (1–50)
0 1–5 6–10 11–20 ≥21 No answer
0 % 46.7 % 20.0 % 13.3 % 13.3 % 6.7 %
What is the number of maternal PKU pregnancies followed over the course of a typical year at your clinic/centre? 2 (0–17)
0 1–5 6–10 11–20 ≥21 No answer
19.4 % 58.1 % 6.5 % 3.2 % 0 % 12.9 %
Approximately what percentage of PKU patients currently followed at your centre were late diagnosed? 10 (0–100)
0 % 1–5 % 6–10 % 11–20 % ≥21 % No answer
6.5 % 29.0 % 19.4 % 25.8 % 12.9 % 6.5 %
The PKU team at your centre includes which of the following?a N/A
Physicians
(any type)
Clinical biochemists Psychologists Dieticians/nutritionists
(any type)
Nurses specialising in PKU Research
scientists
Otherb
100 % 58.1 % 54.8 % 71.0 % 25.8 % 29.0 % 9.7 %
Who cares for PKU patients from the age of 18 years?a N/A
PKU paediatric clinic PKU adult clinic Otherc
71.0 % 16.1 % 16.1 %
N/A not applicable, PKU phenylketonuria
aMultiple answers were possible, and therefore, the total exceeds 100 %
b ‘Other’ was specified as ‘molecular geneticist’, ‘laboratory technician’, and ‘neurologist’ in three surveys
c ‘Other’ was specified as (number of questionnaires): ‘Department of Genetics’ (3), ‘adult neurologists (1), ‘metabolic physicians’ (1) and ‘general
practitioner’ (1)
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protein foods) (Table 3), whereas BH4 and large neutral amino
acids were available in 48 and 32% of centres, respectively (in
Poland BH4 treatment was only available for patients with
BH4 deficiency).
Blood Phe thresholds for starting low-Phe diet treatment in
different patient groups are presented in Fig. 2. For newborns,
the most common blood Phe threshold for initiation of treat-
ment was ≥360 μmol/L (65 %; other thresholds used were
≥240 μmol/L [19 %], ≥400 μmol/L [6 %], ≥600 μmol/L
[10 %]). For young and older children, this was also
≥360 μmol/L (64 and 56 %, respectively), whereas for ado-
lescents and adults, it was ≥600 μmol/L (52 and 65%, respec-
tively). Phe thresholds to commence treatment were not al-
ways the same between centres in the same country (data
not shown).
Seventy-one percent of centres started administering low-
Phe diet treatment before 15 days of a patient’s life, with 26%
reporting this to be >15 days (Table 3). The median dose of
Table 2 Summary of screening and confirmatory diagnostic practices (N=31)
Question and answers by category Median (range)
At what age is the heel prick test performed at your centre? 3 (2–7)
0–1 days 2 days 3 days 4 days ≥5 days No answer
0 % 19.4 % 71.0 % 3.2 % 3.2 % 3.2 %
At what age are positively screened newborns seen in the medical service? 10 (3–30)
0–9 days 10–15 days 16–28 days ≥29 days No answer
41.9 % 35.5 % 16.1 % 3.2 % 3.2 %
What is the blood Phe level cut-off for a positive neonatal screening test in your country? N/A
120 μmol/L 180 μmol/L 240 μmol/L 360 μmol/L Othera No answer
48.4 % 25.8 % 9.7 % 3.2 % 9.7 % 3.2 %
For which patient age groups does your centre perform the BH4 loading test?b N/A
Newborns Infants Young children Older children Adolescents Adults No answer
38.7 % 9.7 % 25.8 % 32.3 % 22.6 % 3.2 % 35.5 %
What is the duration of the BH4 loading test? N/A
8 h 24 h 48 h 72 h 7 days 30 days No answer
0 % 35.5 % 9.7 % 9.7 % 0 % 3.2 % 41.9 %
What percentage of patients at your centre are BH4 responders? 15 (0–31)
0 % 1–5 % 6–10 % 11–20 % ≥21 % No answer
3.2 % 9.7 % 6.5 % 9.7 % 12.9 % 58.1 %
BH4 sapropterin dihydrochoride, N/A not applicable, Phe phenylalanine
a ‘Other’ was specified by three questionnaires as 80, 132 and 150 μmol/L
bMultiple answers were possible, and therefore, the total exceeds 100 %
240 µmol/L       360µmol/L       400µmol/L       600µmol/L     Other
80%
70%
60%
50%
40%
30%
20%
10%
0%
Newborns 
and infants
(n=33)
Young 
children
(n=30)
Older 
children
(n=29)
Adolescents
(n=29)
Adults
(n=24)
Pregnant 
women
(n=22)
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65
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9
Fig. 2 Blood Phe threshold levels for starting low-Phe diet treatment in
each patient group (consistently elevated levels), ‘n’ represents the num-
ber of questionnaires which provided an answer for each group (total
responses); ‘Other’ was specified for adolescents as ‘480 μmol/L’, and
for adults as ‘130–900’ and ‘900 μmol/L’; age groups were as follows:
newborns and infants, <1 year of age; young children, 1–4 years of age;
older children, 5–10 years of age; adolescents, 11–17 years of age; adults,
≥18 years of age
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total protein (natural and Phe-free L-amino acid supplement)
prescribed to newborns and infants with classical PKU was
2.5 g/kg/day (median [range] lower limit 2.50 [1.0–3.0] g/kg/
day, median upper limit 2.50 [2.0–3.5] g/kg/day), which de-
creased steadily with increasing patient age to 1 g/kg/day in
adults (median [range] lower limit 1.0 [0.7–1.5] g/kg/day, me-
dian upper limit 1.0 [0.7–1.8] g/kg/day) (Fig. 3).
Low-Phe diet was available to treat maternal PKU at all
centres, although only 22 centres indicated in their question-
naire the Phe level thresholds used to initiate treatment in
maternal PKU. This was either ≥240 μmol/L (74 %) or
≥360 μmol/L (26 %; Fig. 2).
With respect to reimbursement and social support, govern-
ments contributed to costs of Phe-free L-amino acid supple-
ments in the majority of centres (97 %), although there was
less governmental support to cover costs of special low-
protein foods (59 %; Table 3). Patients at most centres were
entitled to a disability allowance and/or a disability certificate
to cover out of pocket costs (81 %), although there was no
social support available for patients at three centres (one in
each of Bulgaria, Hungary and Turkey) (Table 3).
Follow-up practices
A specific follow-up protocol for patients with PKU was used
in 77.4 % of centres (Table 4). Most centres collected blood
samples from the patient’s home (74.2 %) and in outpatient
clinics (67.7 %), and 61 % returned blood Phe results within
4 days (range 1–8 days), using e-mail, phone, letter and clinic
visits (data not shown).
The median percentage of patients ‘lost to follow-up’ (as
defined by a patient not being seen for over 2 years) was 10%.
There was a general trend for higher lost to follow-up rates in
the larger centres. Among the centres providing this data, the
13 largest centres (range of patients 130–2500) had a median
of 15 % patients lost to follow-up, whereas this was 5 % for
the 13 smallest centres (range of patients 3–123).
Blood Phe level target ranges are presented in Fig. 4a. With
a few exceptions, the lower Phe target was 120 μmol/L across
all age groups. The median (range) upper Phe level target was
240 μmol/L (180–600) in newborns, 360 μmol/L (180–900)
in children, and 600 μmol/L (360–1200) in teenagers and
adults. Upper Phe targets were more variable across centres
than lower Phe levels targets, with the interquartile range
spanning >100 μmol/L for newborns and infants, young chil-
dren and adults. With respect to the frequency of Phe moni-
toring, there was a general trend towards less frequent moni-
toring with increasing patient age (Fig. 4b).
In maternal PKU, the median (range) of the upper blood
Phe target while on treatment was 240 μmol/L (120–360)
(Fig. 4a), and Phe level monitoring was most commonly on
a weekly basis (13/23; 57 %), with 3/23 (13 %) centres mon-
itoring every 2 weeks (Fig. 4b).
Guidelines, registries and organisations devoted to PKU
A variety of guidelines and protocols for PKU diagnosis and
treatment were in use across the centres: while 32% of centres
used only published guidelines/protocols, 32 % used only
their own unpublished guidelines/protocols and 29 % of cen-
tres used a mixture of both types. Eighty-five percent of cen-
tres were aware of either a local or national PKU registry, and
94 % were aware of patient/family organisations.
Challenges and areas for improvement
Participants were asked to describe the main challenges
that they face in terms of screening, diagnosis and treat-
ment of PKU; a summary of this feedback is presented
in Online Resource 3.
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Fig. 3 Dose of total protein
(g/kg/day) prescribed to patients
with classical PKU by each centre
per patient age group. Box and
whisker plot, with boxes
representing interquartile range
(thick line indicating the median,
with value indicated in the plot),
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the number of questionnaires
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17 years of age; adults, ≥18 years
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Centres providing demographic data only/e-mail
responses
Four centres (Bosnia and Herzegovina, Republic of Macedo-
nia, Romania and Serbia) provided only demographic data.
These centres collectively cared for 27 patients with PKU, a
high proportion of whomwere late diagnosed (range 20–90%
of patients). The Republic of Macedonia was previously re-
ported to have no newborn screening for PKU [9], and the
contacted centre indicated via e-mail that they manage the
sporadic cases they encounter with an occupational therapy
plan.
Two centres (Albania and Montenegro) provided only
short responses by e-mail, each reporting that there was no
PKU screening in their respective countries.
Discussion
Challenges in diagnosis and treatment
A well-documented issue for PKU care is that management
guidelines differ between countries, often in important areas
such as newborn screening, target blood Phe levels in different
patient groups, frequency of Phe monitoring and duration of
treatment [29]. Our survey adds to a growing body of evi-
dence showing a difference in PKU care between Western
and South and Eastern Europe and provides further reason to
support efforts to raise and standardise treatment across
Europe.
The most critical disparity concerns the lack of newborn
screening in several centres, thereby leading to late com-
mencement of treatment. Results from this survey and com-
plementary studies [9, 11] highlight that although newborn
screening is widespread, it is not yet implemented in all Eu-
ropean countries. This includes five of the target countries of
this survey, namely Albania, Kosovo (from where no infor-
mation was returned), Malta, Montenegro and the Republic of
Macedonia (Fig. 1). Furthermore, in some countries with
established newborn screening programmes, including Bul-
garia and Romania, up to 10 % of newborns are not screened
[9]. Based on these data and current birth rates [6, 9], there
were approximately 170,000 live births unscreened in 2013
across the target countries of this survey. Considering an esti-
mated PKU prevalence of 1/10,000 live births [16], 17 new-
borns per year may face a delayed diagnosis across these
countries.
Our results from 31 centres providing complete question-
naires (of which 30 had newborn screening) suggest that di-
agnostic testing is not always comprehensive or optimally
managed in the region. For example, fewer than half of the
centres reported using specific tests, such as pterins and
DHPR analysis, to diagnose BH4 deficiency. Also, the routine
use of BH4 loading tests was linked to the availability of BH4
Table 3 Summary of treatment and reimbursement information (N=31)
What treatment options are available in your country?
Low-Phe
diet
BH4 Large neutral amino acids Othera
100 % 48.4 % 32.3 % 3.2 %
At what age does your centre introduce low-Phe diet in newly diagnosed newborns?
0–9 days 10–15 days 16–28 days ≥29 days No answer
19.4 % 51.6 % 22.6 % 3.2 % 3.2 %
Who contributes to the costs of Phe-free protein substitutes?b
Government Private health insurance Parents/patients
96.8 % 12.9 % 22.6 %
Who contributes to the cost of special low-protein foods (flour, pasta)?b
Government Private health insurance Parents/patients Otherc
59.4 % 12.5 % 75.0 % 6.3 %
What kind of social support is offered to PKU patients in your country?b
Disability
allow-
ance
Disability certificate which helps with
education, employment, travel
expenses
Dietary allowance to
go to summer
camps
Reimbursement
of travel
expenses
Home support or compensation to
parents for decreasing working
hours
No support
available
80.6 % 45.2 % 32.3 % 25.8 % 12.9 % 9.7 %
BH4 sapropterin dihydrochoride, Phe phenylalanine, PKU phenylketonuria
a ‘Other’ was specified as ‘BH4 only for BH4-deficient patients’
bMultiple answers were possible, and therefore, the total exceeds 100 %
c ‘Other’ was specified as: ‘sellers’, ‘non-governmental organisation’ and ‘parents/patients association’
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treatment for patients with PKU, and a lack of BH4 testing and
treatment were highlighted as main challenges/areas for im-
provement (Online Resource 3). Nevertheless, use of some
advanced diagnostic techniques was surprisingly widespread:
genetic analysis was routinely used in 13 of the countries
represented in this survey, higher than reported elsewhere [1].
Another concern is the time taken for positively screened
patients to be seen at some centres, which was over 2 weeks in
20 % of centres and over 1 month in one centre, and was
mirrored by a similar delay in starting treatment at these cen-
tres. By contrast, US guidelines recommend that initiation of
treatment for PKU should preferably occur within the first
week of life, with the aim to have achieved target blood Phe
concentrations within the first 2 weeks of life [30].
Regarding the professionals within the treatment teams,
there was a notable lack of dedicated dieticians in 30 % of
the centres in this survey (compared with only 6 % in the
predominantly Western European survey [1]). Dieticians are
key to ensuring best management of the complex dietary re-
quirements of patients with PKU [7, 17]. The general lack of
all core professionals within treatment teams and of
specialised adult PKU clinics has also been reported else-
where, including in countries with advanced management ap-
proaches [1, 26, 27].
A striking statistic was the relatively large number of pa-
tients per centre who lived within large catchment areas. There
were approximately two times more patients per centre than in
a predominantlyWestern European survey [1], and themedian
travel distance to the centre was over 100 km. This could
impact care in two ways. Firstly, an increased patient load
may put increased strain on resources (additional information
on patient staffing levels will be needed to assess this possi-
bility, see ‘Sect. Limitations of study’). Secondly, living fur-
ther than approximately 160 km from the care centre has been
associated with significantly fewer Phe samples for analysis
[8], which raises the possibility that distance may impact out-
comes. The proportion of patients lost to follow-up (median of
10 % in this survey), might also be influenced by the size of
these catchment areas and patient loads. This situation might
be caused by countries adopting a ‘tertiary referral hospital’
model, which might not be optimal in all countries. Notably, it
could add to out-of-pocket costs of patients travelling to the
centres. Individual countries should review whether it is more
effective to redistribute resources at a more local level for
managing PKU care.
Commencement and management of treatment was also
not always optimal. Inconsistencies across centres in the Phe
level thresholds to start treatment and upper Phe level targets
during treatment is a universal issue [1, 11] and may lead to
different outcomes for patients with an otherwise similar con-
dition [12]. Monitoring frequency followed the expected trend
of being most frequent in newborns and declining with in-
creasing patient age, although this was also variable across
centres. Importantly, in maternal PKU, 10 % of centres mon-
itored Phe levels only once every 2 weeks, which is sub-
optimal given the changing Phe requirements during pregnan-
cy and risks associated with both high and low Phe concen-
trations: very low levels are associated with intrauterine
growth retardation; high levels (>360 μmol/L) carry a high
risk of maternal PKU syndrome [13, 25]. It is hoped that
several of these issues will be addressed in the near future
by the release of Pan-European guidelines [11].
A lack of treatment options (i.e. availability of BH4, variety
of protein substitutes and foods) featured as a main challenge,
as noted elsewhere [1, 11]. About half of centres relied only on
low-Phe diet, and some felt that the variety of Phe-free protein
substitutes and low-protein foods available to patients was
limited due to a lack of reimbursement. These issues could
decrease adherence to a low-Phe diet [18]. Given the relatively
low income of many families in the surveyed countries, the
Table 4 Summary of follow-up practices (N=31)
Question and answers by category Median (range)
Does your centre follow a specific follow-up protocol for PKU patients? N/A
Yes No No answer
77.4 % 19.4 % 3.2 %
Where does your centre collect samples for monitoring Phe levels in treated PKU patients?a N/A
Home Outpatient clinic Hospital Family doctor clinic (general practitioner)
74.2 % 67.7 % 35.5 % 29.0 %
What is the average return time of routine Phe control results to your patients, after blood sampling? N/A
1–2 days 3–4 days 5–6 days 7–8 days No answer
25.8 % 35.5 % 16.1 % 19.4 % 3.2 %
What proportion of your patients is lost to follow-up (defined as patient was not seen for two years)? 10 (0–21)
0 % 1–5 % 6–10 % 11–20 % ≥21 % No answer
9.7 % 22.6 % 22.6 % 25.8 % 3.2 % 16.1 %
N/A not applicable, Phe phenylalanine, PKU phenylketonuria
aMultiple answers were possible, and therefore, the total exceeds 100 %
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cost and availability of low-Phe foods is an important issue
that must be addressed by healthcare systems and govern-
ments. BH4 treatment is expected to become more widely
available in the coming years, although reimbursement issues
are likely to affect its impact.
Limitations of study
This analysis is subject to several limitations. Unfortunately,
of the five countries known to lack newborn screening, only
one centre in Malta provided a completed questionnaire. Cen-
tres in The Republic of Macedonia, Albania and Montenegro
provided limited information and no response was received
from Kosovo, meaning that we were unable to comprehen-
sively evaluate standard of care in these locations. The number
of patients with PKU in the region who remain undiagnosed is
also unknown and is likely to be a major issue in areas
where newborn screening was only introduced recently
(e.g. in Romania, nationwide newborn screening was
only introduced in 2011 [9]). Thus, there may be se-
verely intellectually disabled patients living without a
correct diagnosis or appropriate medical care not
recognised by this survey [19, 21, 28].
Several targeted centres did not answer the questionnaire.
Literature-based estimates put the population with PKU in the
surveyed region at around 19,000 patients [16], which sug-
gests a 45% coverage by this survey. A lack of translation into
the local language or poor access to computers and/or the
internet may have hampered questionnaire completion by
some centres. Additionally, contacts were lacking for Belarus,
and the list of contacts for other countries may not have been
exhaustive (although in an additional question, the 31 centres
in the main results section indicated that a cumulative total of
45 centres existed across their countries, comparable to the 46
that were contacted, so it is likely that very few were omitted;
see Online Resource 1 and 2).
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Fig. 4 Blood Phe target ranges
(μmol/L) and frequency of blood
Phe monitoring for different
patient groups. aBox and whisker
plot of blood Phe target ranges per
patient group: boxes represent
interquartile range (thick line
indicating the median, with value
indicated in the plot), and dashed
whiskers minimum and
maximum values. b Frequency
histogram of blood Phe
monitoring frequency. ‘Other’
was as follows: newborns and
infants: ‘sometimes weekly,
sometimes 2-weekly’; young
children: ‘1–2 years: 2-weekly;
2–3 years: 3-weekly; 3–4 years:
monthly’; older children: not
specified; adolescents: ‘2-weekly
or monthly’ ‘depends on patient
collaboration’; not specified;
adults: ‘It depends on the patient
collaboration’, not specified; ma-
ternal PKU: ‘sometimes weekly,
sometimes 2X per week’; not
specified (2). ‘n’ represents the
number of questionnaires which
provided an answer for each
group. Age groups were as fol-
lows: newborns and infants,
<1 year of age; young children, 1–
4 years of age; older children, 5–
10 years of age; adolescents, 11–
17 years of age; adults, ≥18 years
of age
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The centres in this survey care for different numbers of
patients with PKU, and therefore, some apply a management
approach which affects far more patients than others (whereas
the size of each centre is not weighted in the above analysis). It
should also be noted that neither the extent to which each
member of the treatment team is dedicated to PKU, nor staff
to patient ratios were established. These two factors play an
important role in the delivery of care.
Finally, the questionnaire used non-validated questions,
which were open to misinterpretation.
Conclusion
Results of this survey point to several important areas for
improvement in PKU diagnostic and management practices
across Southern and Eastern Europe. Given that there remain
parts of Europe where there is no routine newborn screening
(or it has only been recently introduced), older patients with
PKUwho can benefit from low-Phe diet treatment [14, 31] are
likely under-diagnosed. Interestingly, coverage of newborn
screening and diagnostic techniques may not necessarily be
related to the economic standing of the country [9]. Further-
more, the diagnostic and treatment packages offered to pa-
tients may be more influenced by the interests and skills of
the PKU teams rather than the direct needs of the patients.
New evidence-based Pan-European guidelines are currently
in development with the aim of encouraging a common stan-
dard of care [11]. It is important that development of new
guidelines coincides with efforts by HCPs and governments
across the region to ensure all patients receive the best possible
care.
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Appendix
Contributing HCPs and centres.
Bulgaria: Radka Tincheva, Aleksei Savov, Adil Kadam
(University Pediatric Hospital Sofia); Croatia: Vladimir
Sarnavka, Ivo Barić (University Hospital Centre Zagreb);
Czech Republic: Dagmar Prochazkova (I.dětská interní
klinika FN Brno), Renata Pazdírková, Jana Komárková, Hana
Kothánková (Klinika dětí a dorostu FNKV, Praha); Estonia:
Katrin Ounap, Karit Reinson, Mari-Liis Uudelepp (Tartu Uni-
versity Clinicum, Tartu); Hungary: László Szőnyi, Erika Kiss,
Péter Reismann (Semmelweis University, Hungary); Latvia:
Rita Lugovska, Parsla Vevere (Children clinical university
hospital, Riga); Lithuania: Loreta Cimbalistiene (Vilnius Uni-
versity, Vilnius); Malta: Simon Attard Montalto (Mater Dei
Hospital, University of Malta); Poland: Agnieszka Chrobot,
Izabela Horka (Bydgoszcz), Bożena Didycz, Mirosław Bik-
Multanowski (Kraków), Bożena Mikołuć, Maria Jolanta
Piotrowska-Depta, Ewa Samocik (Białystok), Ewa
Starostecka, Agata Lange (Łódź), Jolanta Wierzba, Joanna
Jagłowska (Gdańsk), Kalina Plutowska-Hoffmann, Joanna
Zarębska (Katowice), Maria Giżewska, Hanna Romanowska,
Elżbieta Krzywińska-Zdeb (Szczecin), Maria Nowacka,
Joanna Żó łkowska, Dorota Korycińska-Chaaban
(Warszawa); Republic of Moldova: Usurelu Natalia (Institute
of Mother and Child, Chisinau); Romania: Anton-Paduraru
Dana-Teodora (Spitalul clinic de urgenta pentru copii BSf.
Maria^, Iași), Mariana Muresan (Clinica de Pediatrie III, Cluj
Napoca), Nanu Michaela Iuliana, Moldovanu Florentina,
Iorgulescu Daniela (IOMC Bucuresti, Bucharest); Serbia:
Maja Đorđević, Božica Kecman, Adrijan Sarajlija (Institut
za zdravstvenu zaštitu majke i deteta Srbije, Novi Beograd),
Slovakia: Katarína Hálová (Detská fakultná nemocnica,
Banska Bystrica); Slovenia: Mojca Zerjav Tansek (University
Clinical Center Ljubljana); Turkey: Burcu Öztürk Hişmi
(Çocuk Metabolizma Hastalıkları ve Beslenme Uzmanı Gazi-
antep Çocuk, Gaziantep); Serap Sivri (Hacettepe University
Faculty of Medicine, Hacettepe); Isil Ozer (Medeniyet Uni-
versity, Istanbul, Turkey); Mahmut Coker, Sema Kalkan Ucar
(Ege University, Izmir); Neslihan önenli Mungan, Deniz Kör,
Berna şeker Yilmaz (Cukurova University, Adana), Nur
Arslan, Yesim Ozturk (Dokuz Eylul University, Izmir); Selda
Bulbul (Kirikkale University, Turkey).
Centres providing e-mail/incomplete questionnaire
responses.
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Albania: Lindita Grimci (University Hospital Center
BMother Teresa^, Tirana); Bosnia and Herzegovina: Smail
Zubcevic (Clinical Center University of Sarajevo, Faculty of
Medicine); Montenegro: Mira Samardzic (Institute for Sick
Children, Podgorica); Republic of Macedonia: Elena
Sukarova Angelovska, Natalija Angelkova (University Chil-
dren’s Hospital Skopje); Romania: Otilia Marginean,
Marinela Lesovici (Spitalului Clinic de Urgenta Pentru Copii
BLouis Turcanu^, Timisoara); Serbia: Jovanovic Privrodski
Jadranka, Kavecan Ivana (Institut Za Decu i Omladinu, Novi
Sad).
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